178 related articles for article (PubMed ID: 20368223)
1. What are the practical implications for treating diabetes in light of recent evidence? Updated recommendations from the Global Partnership for Effective Diabetes Management.
Bailey CJ; Blonde L; Del Prato S; Leiter LA; Nesto R;
Diab Vasc Dis Res; 2009 Oct; 6(4):283-7. PubMed ID: 20368223
[TBL] [Abstract][Full Text] [Related]
2. Individualized glycaemic targets and pharmacotherapy in type 2 diabetes.
Bailey CJ; Aschner P; Del Prato S; LaSalle J; Ji L; Matthaei S;
Diab Vasc Dis Res; 2013 Sep; 10(5):397-409. PubMed ID: 23711582
[TBL] [Abstract][Full Text] [Related]
3. Optimal glycaemic control in elderly people with type 2 diabetes: what does the evidence say?
Mathur S; Zammitt NN; Frier BM
Drug Saf; 2015 Jan; 38(1):17-32. PubMed ID: 25481812
[TBL] [Abstract][Full Text] [Related]
4. Tailoring treatment to the individual in type 2 diabetes practical guidance from the Global Partnership for Effective Diabetes Management.
Del Prato S; LaSalle J; Matthaei S; Bailey CJ;
Int J Clin Pract; 2010 Feb; 64(3):295-304. PubMed ID: 20456169
[TBL] [Abstract][Full Text] [Related]
5. The 2018 update of the American College of Physicians glycaemic management recommendations: An invitation to continued inertia?
Morales J; Assumpcao-Morales M
Diabetes Obes Metab; 2018 Aug; 20(8):1809-1811. PubMed ID: 29658190
[TBL] [Abstract][Full Text] [Related]
6. Individualizing glycemic targets in type 2 diabetes mellitus: implications of recent clinical trials.
Ismail-Beigi F; Moghissi E; Tiktin M; Hirsch IB; Inzucchi SE; Genuth S
Ann Intern Med; 2011 Apr; 154(8):554-9. PubMed ID: 21502652
[TBL] [Abstract][Full Text] [Related]
7. Glycemic Targets in Diabetes Care: Emerging Clarity after Accord.
Buse JB
Trans Am Clin Climatol Assoc; 2015; 126():62-76. PubMed ID: 26330660
[TBL] [Abstract][Full Text] [Related]
8. Initial monotherapy with either metformin or sulphonylureas often fails to achieve or maintain current glycaemic goals in patients with Type 2 diabetes in UK primary care.
Cook MN; Girman CJ; Stein PP; Alexander CM
Diabet Med; 2007 Apr; 24(4):350-8. PubMed ID: 17335466
[TBL] [Abstract][Full Text] [Related]
9. HbA1c targets in type 2 diabetes: guidelines and evidence.
Drug Ther Bull; 2013 Apr; 51(4):42-5. PubMed ID: 23557845
[TBL] [Abstract][Full Text] [Related]
10. Glycemic control in type 2 diabetes: time for an evidence-based about-face?
Montori VM; Fernández-Balsells M
Ann Intern Med; 2009 Jun; 150(11):803-8. PubMed ID: 19380837
[TBL] [Abstract][Full Text] [Related]
11. Improving glucose management: ten steps to get more patients with type 2 diabetes to glycaemic goal.
Del Prato S; Felton AM; Munro N; Nesto R; Zimmet P; Zinman B;
Int J Clin Pract; 2005 Nov; 59(11):1345-55. PubMed ID: 16236091
[TBL] [Abstract][Full Text] [Related]
12. Intensive glucose control and cardiovascular outcomes in type 2 diabetes.
Macisaac RJ; Jerums G
Heart Lung Circ; 2011 Oct; 20(10):647-54. PubMed ID: 20807681
[TBL] [Abstract][Full Text] [Related]
13. Cardiovascular disease and intensive glucose control in type 2 diabetes mellitus: moving practice toward evidence-based strategies.
Meier M; Hummel M
Vasc Health Risk Manag; 2009; 5():859-71. PubMed ID: 19898642
[TBL] [Abstract][Full Text] [Related]
14. Position statement of the Australian Diabetes Society: individualisation of glycated haemoglobin targets for adults with diabetes mellitus.
Cheung NW; Conn JJ; d'Emden MC; Gunton JE; Jenkins AJ; Ross GP; Sinha AK; Andrikopoulos S; Colagiuri S; Twigg SM;
Med J Aust; 2009 Sep; 191(6):339-44. PubMed ID: 19769558
[TBL] [Abstract][Full Text] [Related]
15. Practical steps to improving the management of type 1 diabetes: recommendations from the Global Partnership for Effective Diabetes Management.
Aschner P; Horton E; Leiter LA; Munro N; Skyler JS;
Int J Clin Pract; 2010 Feb; 64(3):305-15. PubMed ID: 20456170
[TBL] [Abstract][Full Text] [Related]
16. The effects of baseline characteristics, glycaemia treatment approach, and glycated haemoglobin concentration on the risk of severe hypoglycaemia: post hoc epidemiological analysis of the ACCORD study.
Miller ME; Bonds DE; Gerstein HC; Seaquist ER; Bergenstal RM; Calles-Escandon J; Childress RD; Craven TE; Cuddihy RM; Dailey G; Feinglos MN; Ismail-Beigi F; Largay JF; O'Connor PJ; Paul T; Savage PJ; Schubart UK; Sood A; Genuth S;
BMJ; 2010 Jan; 340():b5444. PubMed ID: 20061360
[TBL] [Abstract][Full Text] [Related]
17. Long-term 4-year safety of saxagliptin in drug-naive and metformin-treated patients with Type 2 diabetes.
Rosenstock J; Gross JL; Aguilar-Salinas C; Hissa M; Berglind N; Ravichandran S; Fleming D
Diabet Med; 2013 Dec; 30(12):1472-6. PubMed ID: 23802840
[TBL] [Abstract][Full Text] [Related]
18. Mismatch between ADA and AGS recommendations for glycated hemoglobin targets for older adults.
Tasci I; Safer U; Naharci I; Sonmez A
Prim Care Diabetes; 2018 Apr; 12(2):192-194. PubMed ID: 29396204
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of linagliptin in persons with type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea: a 24-week randomized study.
Owens DR; Swallow R; Dugi KA; Woerle HJ
Diabet Med; 2011 Nov; 28(11):1352-61. PubMed ID: 21781152
[TBL] [Abstract][Full Text] [Related]
20. Comparison of biphasic insulin aspart 30 given three times daily or twice daily in combination with metformin versus oral antidiabetic drugs alone in patients with poorly controlled type 2 diabetes: a 16-week, randomized, open-label, parallel-group trial conducted in russia.
Ushakova O; Sokolovskaya V; Morozova A; Valeeva F; Zanozina O; Sazonova O; Zhadanova E; Starceva M; Kazakova E; Saifullina M; Shapiro I; Tarasov A; Al-Tayar B; Starkova N
Clin Ther; 2007 Nov; 29(11):2374-84. PubMed ID: 18158078
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
